Type I Pituitary Adenylate Cyclase-Activating Polypeptide Receptors

A pituitary adenylate cyclase-activating peptide receptor subtype that is found in the HYPOTHALAMUS; BRAIN STEM; PITUITARY GLAND; ADRENAL GLAND; PANCREAS; and TESTES and has a high affinity only for PACAP.

Also Known As:

Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; PAC1 Receptor; PACAP Type I Receptor; PACAPR-1 Protein; PACAPR 1 Protein; Pituitary Adenylate Cyclase Activating Peptide Receptor Type I; PACAP Receptors, Type I; Pituitary Adenylate Cyclase-Activating Peptide Receptor Type I

Networked: 83 relevant articles (5 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - G-Protein-Coupled Receptors: 4701
        Pituitary Adenylate Cyclase-Activating Polypeptide Receptors: 106
        Type I Pituitary Adenylate Cyclase-Activating Polypeptide Receptors: 83
        human ADCYAP1R1 protein
        mouse Adcyap1r1 protein
        rat Adcyap1r1 protein

Experts

1.	May, Victor: 8 articles (07/2019 - 11/2008)
2.	Reglodi, Dora: 6 articles (01/2021 - 01/2012)
3.	Braas, Karen M: 5 articles (01/2017 - 11/2008)
4.	Ashina, Messoud: 4 articles (01/2021 - 03/2014)
5.	Takasaki, Ichiro: 4 articles (11/2020 - 01/2018)
6.	Kurihara, Takashi: 4 articles (01/2020 - 01/2016)
7.	Miyata, Atsuro: 4 articles (01/2020 - 01/2016)
8.	Hammack, Sayamwong E: 4 articles (01/2017 - 02/2011)
9.	Brabet, Philippe: 3 articles (01/2021 - 01/2002)
10.	Shen, Sanbing: 3 articles (01/2021 - 07/2006)

Related Diseases

1.	Migraine Disorders (Migraine) 12/01/2010 - "The present thesis contributes to our knowledge on migraine pathophysiology and suggests PAC1 receptor antagonism as a new target for migraine treatment." 10/07/2015 - "Furthermore, the PAC1 receptor may be an appropriate molecular target for migraine therapeutics. " 01/01/2023 - "Our results demonstrate that inhibition of PAC1 receptor internalization could effectively improve allodynia in CM rats by restraining ERK signaling pathway activation in a chronic migraine rat model. " 01/01/2023 - "Inhibiting PAC1 receptor internalization and endosomal ERK pathway activation may ameliorate hyperalgesia in a chronic migraine rat model." 01/01/2021 - "To assess the safety and efficacy of AMG 301, an inhibitor of the pituitary adenylate cyclase-activating polypeptide (PACAP)-1 (PAC1) receptor, for prevention of migraine. "
2.	Hypoxia (Hypoxemia) 03/15/2017 - "The role of TG2 in PAC1 receptor-induced cytoprotection and neurite outgrowth was investigated by monitoring hypoxia-induced cell death and appearance of axonal-like processes, respectively. " 12/01/2021 - "These results suggest that hypoxia induces oxidative stress, apoptosis, and neurites disruption, while MPAPO is remarkably protective against these adverse effects of hypoxia in TGCs and the developing retinas by specifically activating PAC1 receptor." 03/15/2017 - "Role of transglutaminase 2 in PAC1 receptor mediated protection against hypoxia-induced cell death and neurite outgrowth in differentiating N2a neuroblastoma cells."
3.	Neuroblastoma 02/01/2006 - "PAC1 receptor splice variants missing a 21 amino acid sequence in the amino terminal domain were found to be the major receptor variants in the neuroblastoma cell lines and also were highly expressed in embryonic brain compared to adult brain. " 03/15/2017 - "In this study, we investigated the regulation of TG2 activity by the PAC1 receptor in retinoic acid-induced differentiating N2a neuroblastoma cells. " 03/01/2006 - "Stimulation of endogenously expressed PAC1 receptors with PACAP in human neuroblastoma cells increased APPsalpha secretion, which was completely inhibited by the PAC1 receptor specific antagonist PACAP-(6-38). " 02/01/2006 - "Characterization of novel splice variants of the PAC1 receptor in human neuroblastoma cells: consequences for signaling by VIP and PACAP." 03/15/2017 - "Role of transglutaminase 2 in PAC1 receptor mediated protection against hypoxia-induced cell death and neurite outgrowth in differentiating N2a neuroblastoma cells."
4.	Wounds and Injuries (Trauma) 01/01/2012 - "Expression of endogenous PACAP and its specific PAC1 receptor is elevated in different parts of the central and peripheral nervous system after traumatic injuries. " 03/02/2018 - "In the present review we summarize the protective effects of PACAP in ischemia, especially in neuronal ischemic injuries, and discuss possible points to consider when developing strategies in migraine therapy interfering with the PACAP/PAC1 receptor system."
5.	Ischemia 03/02/2018 - "In the present review we summarize the protective effects of PACAP in ischemia, especially in neuronal ischemic injuries, and discuss possible points to consider when developing strategies in migraine therapy interfering with the PACAP/PAC1 receptor system."

Related Drugs and Biologics

1.	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)
2.	Protein Glutamine gamma Glutamyltransferase 2
3.	MPAPO
4.	Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
5.	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)
6.	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
7.	Neuropeptides
8.	Fibrinogen (Factor I)
9.	Tretinoin (Retinoic Acid)
10.	Nitric Oxide (Nitrogen Monoxide)

Related Therapies and Procedures

1.	Therapeutics
2.	Spinal Injections
3.	Critical Care (Surgical Intensive Care)